<DOC>
	<DOCNO>NCT00501384</DOCNO>
	<brief_summary>The primary objective determine optimal dose range dos SR121463B reduction recurrence ascites , use concomitantly standard dose regimen spironolactone . The secondary objective determine tolerability different fix dos SR121463B cirrhotic ascites , 12-week treatment period . This SPA study follow single-blind , placebo-controlled , 40 week long-term safety extension ( ExSPA ) . The first extension follow another long-term study ( PASCCAL-1 ) .</brief_summary>
	<brief_title>Satavaptan Dose-Ranging Study Prevention Ascites</brief_title>
	<detailed_description />
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Satavaptan</mesh_term>
	<criteria>Cirrhosis liver confirm ultrasound , endoscopic examination biochemical evidence Patients undergone therapeutic paracentesis removal ascites previous 24 hour removal â‰¥4 L fluid Patients undergone least 1 therapeutic paracentesis previous 3 month The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>cirrhotic ascites</keyword>
</DOC>